Business Context and Reporting Period
This Form 8-K filing by Fox Factory Holding Corp. is dated January 13, 2017, reporting events that occurred on January 12, 2017. The filing addresses a corporate governance matter regarding the composition of the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change in board composition and does not contain financial performance data.
Material Changes
- Board Resignation: Joseph W. Hagin, an independent director, resigned from the Board of Directors effective January 12, 2017.
- Listing Non-Compliance: As a result of the resignation, the Board no longer comprises a majority of independent directors, violating NASDAQ Listing Rule 5605(b)(1).
- Regulatory Notification: The Company notified NASDAQ of the non-compliance and requested a cure period under NASDAQ Listing Rule 5605(b)(1)(A).
Outlook, Risks, and Management Commentary
Cure Period: NASDAQ has acknowledged the non-compliance and granted a cure period. The Company must regain compliance by the earlier of its next annual shareholders' meeting or January 12, 2018. If the next annual meeting is held before July 12, 2017, the deadline is July 12, 2017.
Management Plan: The Company intends to identify a candidate to replace Mr. Hagin and appoint a director who satisfies NASDAQ independence requirements before the cure period expires.
Risks: Failure to regain compliance within the cure period could result in delisting from the NASDAQ stock market.
Key Facts for Investor Verification
- Verify the date of the next annual shareholders' meeting to determine the exact deadline for restoring board independence.
- Monitor future filings for the appointment of a new independent director.
- Confirm that the Company maintains communication with NASDAQ regarding the status of the cure period.